Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tarlatamab + temozolomide
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Tarlatamab + temozolomide is an investigational combination therapy being evaluated for the treatment of DLL3-positive high-grade central nervous system (CNS) tumors, including high-grade gliomas. Tarlatamab is a bispecific T-cell engager (BiTE) designed to bind to Delta-like ligand 3 (DLL3) on tumor cells and CD3 on T-cells, facilitating T-cell-mediated tumor cell lysis. Temozolomide is an oral alkylating agent that induces DNA damage by methylating guanine residues. This combination, studied in the TARLATEM trial sponsored by Centre Leon Berard in collaboration with Amgen, aims to leverage the immunotherapeutic activity of tarlatamab alongside the cytotoxic effects of metronomic temozolomide in patients with high-grade brain tumors.
- Other names
- AMG-757AMG757AMG 757TemozolomideMetronomic temozolomideTARLATEM
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)DNA
Beyond the preview
Go deeper on tarlatamab + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tarlatamab + temozolomide.